The Motley Fool

Why I believe Neil Woodford could still make you amazingly rich

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Two years ago, Neil Woodford ruled supreme. His eponymous fund CF Woodford Equity Income had thrashed all comers in the year since launch in June 2014, returning a thumping 16.2% against just 5.3% across the UK Equity Income sector. Investor money duly flooded in.

In Neil we trust

When he launched Woodford Patient Capital Trust the following April it instantly attracted £500m, even though this was an entirely new venture for him, an investment trust focusing on early-stage companies. Then it started to go wrong.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

CF Woodford Equity Income’s second discrete performance year undermined the myth of invincibility, growing just 3.8% against 9.8% on its benchmark, according to In year three it fell 0.1%, while its benchmark grew a whopping 11.1%. No Superman, he.


If you thought that was ugly, cover your eyes. Woodford Patient Capital Trust fell 9.9% then 6.5% over its first two years, against growth of 3.7% and 18% on its benchmark, the All Companies index. He has also suffered embarrassing stock disasters: Provident Financial, AstraZenecaAllied MindsAA and in his investment trust, Sphere Medical Holdings. The cry went up: what’s going wrong with Woodford?

I have been scouring performance charts for signs of a recent comeback but over the last three months, CF Woodford Equity Income is down 2.4%, against a 3.2% rise on its benchmark.

He is responding as he always has when the cycle turns against him: by hunkering down, ignoring the hype, and trusting his judgement. He did it when he shunned the dotcom boom in the late 1990s and banking stocks before the financial crisis. Performance slipped, analysts became sniffy, investors baulked and history proved him right.

Red peril

Today he says the economy is in a bubble again, and he is positioned to benefit when it “inevitably bursts”. He can see so many “lights flashing red” he is losing count, including Bitcoin’s surge, European junk bonds yielding less than US Treasuries, historically low volatility and triple-leveraged ETFs attracting gigantic inflows.

Woodford notes that during every bubble a subset of stocks is dumped as investors rush to catch the latest fashion. He is hoovering up these uncool stocks, of which AstraZeneca is a good example, and biding his time, saying this is “an opportunity to capture assets at incredibly depressed valuations, the likes of which I have only seen two or three times during my 30-year career.”

Trouble with bubbles

Woodford isn’t the only one worried about heady valuations. The US has only been this expensive three times before, in 1929, 1999 and 2007. Nor is he the only one to note that after recent underperformance the UK looks relatively cheap.

The problem with calling a correction is that you are trying to time the market, which is impossible. Bubbles typically blow for longer than people expect and with the IMF predicting strong economic growth next year, this one could carry on inflating. So 2018 could be another year of pain for Woodford. The cycle will one day swing his way, because cycles do. Neil Woodford could still make you amazingly rich, if you are patient.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Harvey Jones owns units in CF Woodford Equity Income. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.